These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Beta-casein nanoparticles as an oral delivery system for chemotherapeutic drugs: impact of drug structure and properties on co-assembly.
    Author: Shapira A, Assaraf YG, Epstein D, Livney YD.
    Journal: Pharm Res; 2010 Oct; 27(10):2175-86. PubMed ID: 20703895.
    Abstract:
    PURPOSE: To develop a novel oral drug delivery system comprising a hydrophobic chemotherapeutic drug entrapped within beta casein (β-CN), a major milk protein, which self-associates into micelles in aqueous solutions. The efficient gastric digestibility of β-CN suggests possible targeting to gastric cancers. METHODS: Antitumor drug entrapment was performed by stirring its dimethyl-sulfoxide solution into a phosphate-buffered saline containing β-CN. The association of drugs to β-CN was characterized by spectrophotometry and Trp143 fluorescence quenching; particle-size by dynamic light scattering, and colloidal stability by zeta potential. RESULTS: The optimal drug-to-β-CN molar loading-ratios for paclitaxel and vinblastine at 1 mg/ml β-CN were found to be 7.3 ± 1.2 and 5.3 ± 0.6 and the association constants were (6.3 ± 1.0) x 10(3) M(-1) and (2.0 ± 0.3) x 10(4) M(-1), respectively. Zeta potential analysis suggested that nanoencapsulation by β-CN stabilized all studied drugs in aqueous solution. The initial drug-β-CN association was apparently governed by hydrophobic interactions and at higher drug concentrations, also by electrostatic interactions. Up to the optimal drug:β-CN loading-ratio, ~80% of the particles were below 100 nm in diameter. At higher drug concentrations, particle diameter increased, and bi- or tri-modal particle distributions were observed. CONCLUSIONS: Beta-CN forms colloidally-stable nanovehicles of hydrophobic anticancer drugs, and may be used for oral-delivery of chemotherapeutics.
    [Abstract] [Full Text] [Related] [New Search]